We are preparing the requested document. Please wait, this may take a while...!
|Antigen||Vascular Endothelial Growth Factor A (VEGFA) Antibodies|
|Epitope||Isoform 165 Alternatives|
|Conjugate||This VEGF antibody is un-conjugated Alternatives|
Enzyme Immunoassay (EIA), Functional Studies (Func), Western Blotting (WB)
|2 references available|
|Supplier||Log in to see|
Product Details anti-VEGF AntibodyTarget Details VEGF Application Details Handling References for anti-VEGF antibody (ABIN155173) Images
|Specificity||The antibody recognizes VEGF-A.|
|Cross-Reactivity (Details)||Species reactivity (tested):Human.|
|Purification||Protein G Chromatography|
|Immunogen||Recombinant Human VEGF165 protein (45 kDa)|
Target Details VEGFProduct Details anti-VEGF Antibody Application Details Handling References for anti-VEGF antibody (ABIN155173) Images back to top
|Alternative Name||VEGF-A (VEGFA Antibody Abstract)|
|Background||Human Vascular Endothelial Growth Factor VEGF165, a 23 kDa protein consisting of 165 amino acid residues, is produced as a homodimer. VEGF is a polypeptide growth factor and a member of the platelet-derived growth factor family. It is a specific mitogen for vascular endothelial cells and a strong angiogenic factor in vivo. Two high-affinity tyrosine kinase receptors for VEGF165 have been identified, VEGFR-1 (FLT-1), and VEGFR-2 (KDR). In addition to its action as a mitogen it is a potent vascular permeability factor (VPF) in vivo. VEGF165 is also a chemo attractant molecule for monocytes and endothelial cells. 5 different proteins are generated by differential splicing: VEGF121, VEGF145, VEGF165, VEGF189 and VEGF206. The most abundant form is VEGF165. Whereas VEGF121 and VEGF165 are secreted proteins, VEGF145, VEGF189 and VEGF206 are strongly cell-associated. The isoforms VEGF145, VEGF165 and VEGF189 bind to heparin with high affinity. VEGF165 is apparently a homo-dimer, but preparations of VEGF165 show some heterogeneity on SDS gels, depending on the secretion of different glycosylation patterns. All dimeric forms have similar biological activities but their bioavailability is very different. There is good evidence that different cells and tissues express different VEGF isoforms. The other members of this increasing growth factor family are VEGF-B, -C, -D and -E. Another member is the Placenta growth factor PlGF.Synonyms: VEGF, VEGFA, VPF, Vascular endothelial growth factor A, Vascular permeability factor|
|Research Area||Cytokines, Growth Factors, Receptors, Immunology, Inflammation, Signaling|
|Pathways||RTK Signaling, Glycosaminoglycan Metabolic Process, Regulation of Cell Size, Tube Formation, Signaling Events mediated by VEGFR1 and VEGFR2, Platelet-derived growth Factor Receptor Signaling, VEGFR1 Specific Signals, VEGF Signaling|
Application DetailsProduct Details anti-VEGF Antibody Target Details VEGF Handling References for anti-VEGF antibody (ABIN155173) Images back to top
ELISA: 1-15 μg/mL. Western blot: 2-10 μg/mL. Neutralization: Blocks the VEGF-A induced proliferation of ACE cell at a 1: 6 Molar ratio ofligand to antibody. Inhibits the binding of VEGF-A to the VEGF receptors 1 (Flt-1) and 2 (KDR).
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.
|Restrictions||For Research Use only|
HandlingProduct Details anti-VEGF Antibody Target Details VEGF Application Details References for anti-VEGF antibody (ABIN155173) Images back to top
|Reconstitution||Restore in sterile water to a concentration of 0.1-1.0 mg/mL.|
|Buffer||H2O, Trehalose, Na-Phosphate, Polysorbart20|
|Handling Advice||Avoid repeated freezing and thawing.|
|Storage||4 °C/-20 °C|
|Storage Comment||The lyophilized antibody, thought stable at RT, is best stored desiccated below 0 °C. Reconstituted anti-VEGF-A is stable at 2-8 °C for one month or (in aliquots) at - 20 °C for longer.|
References for anti-VEGF antibody (ABIN155173)Product Details anti-VEGF Antibody Target Details VEGF Application Details Handling Images back to top
Kim, Li, Winer, Armanini, Gillett, Phillips, Ferrara: "Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo." in: Nature, Vol. 362, Issue 6423, pp. 841-4, 1993
Kim, Li, Houck, Winer, Ferrara: "The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies." in: Growth factors (Chur, Switzerland), Vol. 7, Issue 1, pp. 53-64, 1992